% | $
Quotes you view appear here for quick access.

Merrimack Pharmaceuticals, Inc. Message Board

  • nomoneyhomeboy nomoneyhomeboy Apr 3, 2013 1:33 PM Flag

    waitng to hear about mm 398 for pancreatic cancer

    supposed to around mid 2013. mack has all the rights to it, no partner yet

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Some disappointing news today so far but there will also be some good news according to this article below. They are excited about something.

      CAMBRIDGE, Mass., April 2, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research data on five novel experimental cancer therapies (MM-398, MM-121, MM-111, MM-302, and MM-141) will be presented at the 2013 American Association for Cancer Research (AACR) Annual Meeting, April 6-10, 2013 in Washington, DC. Presentations will include preclinical data evaluating the potential of treatments to restore tumor drug sensitivity and delay resistance when used alone or in combination with other targeted treatments. Data will be shared in late-breaking sessions, mini-symposia and poster sessions.

      "We are excited about the advancements and research to be presented regarding several of the therapies in Merrimack's robust oncology pipeline," said Ulrik Nielsen, PhD, Co-Founder and Chief Scientific Officer, Merrimack Pharmaceuticals. "The research explores the potential of our novel medicines to inhibit signaling to prevent tumor growth and improve responsiveness to treatments, as well as the potential of our investigational Nano therapeutics to deliver chemotherapy directly to diseased cells to enhance activity and improve safety. These therapies are being studied across multiple cancers such as head and neck, lung, breast, gastric, pancreatic and melanoma."

      Sentiment: Buy

9.60+0.17(+1.80%)Oct 9 4:00 PMEDT